In lung cancer, promoter KEAP1 methylation and point mutations in functional domains of KEAP1 and NFE2L2 genes are firstly reported in NSCLC [3,4] and then widely described as a specific signature of aggressiveness in many solid tumors, being correlated with overall survival and response of patients to standard treatments [5,6]. This evidence concerns the gene NFE2L2 and lung cancer.